CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
PharmaShijiazhuang, Hebei, China · Est. 1997
CSPC Zhongqi Pharmaceutical Technology Co., Ltd. is a Chinese pharmaceutical company focused on the development and commercialization of innovative drugs and traditional Chinese medicines.
11
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
26
Indications↗
Distinct diseases across all programs
157
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
11 drugs in development
Approved1
Phase 34
Phase 26
Phase 12
By Therapeutic Area
top 6
Oncology
744%
Respiratory
213%
Immunology
213%
Rare Disease
16%
Metabolic & Endocrine
16%
Dermatology
16%
R&D Momentum
65/100
Pipeline Velocity
37/100
Trial Completion Rate
67/100
Pipeline Concentration
24/100
Pipeline Freshness
52/100
Strategic Signals
- ↗Active in Rare Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Recruiting
A Single-Center, Non-Randomized, Open-Label, Parallel-Group Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Multiple Doses of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
Jul 11, 2026
Recruiting
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Liver Function
Earlier
Jan 12, 2026TrialA Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085
Dec 23, 2025TrialSafety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
Dec 18, 2025TrialA Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Nov 13, 2025TrialA Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
Sep 15, 2025TrialHB1801 Combined Treatment of HER2-positive Breast Cancer
Aug 31, 2025TrialA Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)
Details
Company Info
Therapeutic Focus
OncologyCardiovascularAntibiotics
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(1 drug)
—
—
—
1
—
Cardiovascular(1 drug)
Dermatology(1 drug)
—
—
1
—
—
Dermatology(1 drug)
Immunology(2 drugs)
—
1
1
—
—
Immunology(2 drugs)
Metabolic & Endocrine(1 drug)
—
—
—
1
—
Metabolic & Endocrine(1 drug)
Oncology(7 drugs)
—
1
5
3
—
Oncology(7 drugs)
Rare Disease(1 drug)
—
—
—
—
1
Rare Disease(1 drug)
Respiratory(2 drugs)
—
—
2
1
—
Respiratory(2 drugs)
Unknown / Other(1 drug)
—
—
1
—
—
Unknown / Other(1 drug)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)